Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial

What Was Tested

The paper reports a study of Semaglutide, published as a randomized controlled trial.

To compare the effects of oral semaglutide with placebo (primary) and open-label subcutaneous semaglutide (secondary) on glycemic control in patients with type 2 diabetes.

Who Took Part

According to the abstract, 1106 participants were involved.

PubMed indexes the participants as middle-aged adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind, open-label, placebo-controlled and parallel-group study.

Because people in this Semaglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on Semaglutide, so expectations could not easily colour the readings.

Everyone knew when Semaglutide was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

Some participants received a placebo instead of Semaglutide, giving a reference point.

Randomization was stratified by metformin use.

What Was Measured

The subject headings attached to it are Blood Glucose, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Glycated Hemoglobin, Hypoglycemia, Hypoglycemic Agents and Nausea.

What This Means in Plain Language

The paper is a randomized, double-blind and open-label study of Semaglutide in 1106 participants.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 9 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2017 (JAMA), a journal based in United States.

More context: the Semaglutide compound page.